Literature DB >> 15498050

Circulating monocytes in patients with acute coronary syndromes lack sufficient interleukin-10 production after lipopolysaccharide stimulation.

P L van Haelst1, J W Cohen Tervaert, J Bijzet, C Baljé-Volkers, J F May, B Langeveld, R O B Gans.   

Abstract

Acute coronary syndromes (ACS) are associated with inflammation resulting from monocyte activation. We sought for differences in the production of pro- and anti-inflammatory cytokines by monocytes from patients with ACS. C-reactive protein (CRP) and neopterin were measured in 22 patients with acute coronary syndromes, 50 patients with stable vascular disease and 22 healthy controls. Production of tumour necrosis factor (TNF)-alpha and interleukin (IL)-10 was determined after, respectively, 6 and 24 h of incubation of full blood with lipopolysaccharide (LPS). Levels of CRP [median, interquartile range (IQR)][1.5 mg/l (0.8-4.5) ACS patient versus 2.1 (0.9-3.6) stable disease versus 0.4 (0.3-1.2) healthy controls] (P < 0.001) and neopterin [7.4 nmol/l (6.0-8.7) ACS patient versus 7.1(6.0-8.9) stable disease versus 6.4 (5.6-7.3) healthy controls] (P = 0.07) were higher in both the patient groups. IL-10 production after LPS stimulation was greatly reduced in patients with acute coronary syndromes (16 175 pg/ml, 7559-28 470 pg/ml) as opposed to patients with stable disease (28 379 pg/ml, 12 601-73 968 pg/ml) and healthy controls (63 830 pg/ml, 22 040-168 000 pg/ml) (P = 0.003). TNF-alpha production was not signi fi cantly different between the groups [7313 pg/ml (4740-12 615) ACS patient versus 11 002 (5913-14 190) stable disease versus 8229 (5225-11 364) healthy controls] (P = 0.24). Circulating monocytes in unstable coronary syndromes produce equal amounts of TNF-alpha but less IL-10 after stimulation with LPS in vitro as compared with healthy controls. We hypothesize that, in acute coronary syndromes, the production proinflammatory cytokines is not counterbalanced by anti-inflammatory cytokines such as IL-10.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15498050      PMCID: PMC1809199          DOI: 10.1111/j.1365-2249.2004.02602.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  23 in total

1.  Suppression of the clinical and cytokine response to endotoxin by RWJ-67657, a p38 mitogen-activated protein-kinase inhibitor, in healthy human volunteers.

Authors:  J W Fijen; J G Zijlstra; P De Boer; R Spanjersberg; J W Tervaert; T S Van Der Werf; J J Ligtenberg; J E Tulleken
Journal:  Clin Exp Immunol       Date:  2001-04       Impact factor: 4.330

Review 2.  Interleukin-10 and the interleukin-10 receptor.

Authors:  K W Moore; R de Waal Malefyt; R L Coffman; A O'Garra
Journal:  Annu Rev Immunol       Date:  2001       Impact factor: 28.527

3.  Catecholamines induce IL-10 release in patients suffering from acute myocardial infarction by transactivating its promoter in monocytic but not in T-cells.

Authors:  U Riese; S Brenner; W D Döcke; S Prösch; P Reinke; M Oppert; H D Volk; C Platzer
Journal:  Mol Cell Biochem       Date:  2000-09       Impact factor: 3.396

4.  Inflammatory markers in men with angiographically documented coronary heart disease.

Authors:  N Rifai; R Joubran; H Yu; M Asmi; M Jouma
Journal:  Clin Chem       Date:  1999-11       Impact factor: 8.327

5.  Serum neopterin and complex stenosis morphology in patients with unstable angina.

Authors:  X Garcia-Moll; F Coccolo; D Cole; J C Kaski
Journal:  J Am Coll Cardiol       Date:  2000-03-15       Impact factor: 24.094

6.  Tumor necrosis factor (TNF) inhibits interleukin (IL)-1 and/or IL-6 stimulated synthesis of C-reactive protein (CRP) and serum amyloid A (SAA) in primary cultures of human hepatocytes.

Authors:  S H Yap; H J Moshage; B P Hazenberg; H M Roelofs; J Bijzet; P C Limburg; L A Aarden; M H van Rijswijk
Journal:  Biochim Biophys Acta       Date:  1991-02-19

7.  Serum levels of the antiinflammatory cytokine interleukin-10 are decreased in patients with unstable angina.

Authors:  D A Smith; S D Irving; J Sheldon; D Cole; J C Kaski
Journal:  Circulation       Date:  2001-08-14       Impact factor: 29.690

8.  Protective role of interleukin-10 in atherosclerosis.

Authors:  Z Mallat; S Besnard; M Duriez; V Deleuze; F Emmanuel; M F Bureau; F Soubrier; B Esposito; H Duez; C Fievet; B Staels; N Duverger; D Scherman; A Tedgui
Journal:  Circ Res       Date:  1999-10-15       Impact factor: 17.367

9.  Effects of systemic interleukin-10 therapy on psoriatic skin lesions: histologic, immunohistologic, and molecular biology findings.

Authors:  K Asadullah; M Friedrich; S Hanneken; C Rohrbach; H Audring; A Vergopoulos; M Ebeling; W D Döcke; H D Volk; W Sterry
Journal:  J Invest Dermatol       Date:  2001-05       Impact factor: 8.551

Review 10.  T-cell immunity in acute coronary syndromes.

Authors:  C M Weyand; J J Goronzy; G Liuzzo; S L Kopecky; D R Holmes; R L Frye
Journal:  Mayo Clin Proc       Date:  2001-10       Impact factor: 7.616

View more
  3 in total

1.  Effects of ramipril on serum monocyte chemoattractant protein 1, interleukin-18, and interleukin-10 in elderly patients with acute coronary syndrome.

Authors:  Huan-qin Chen; Hong-yong Tan; Yi-wen Yang; Lei Qiu; Xiang-qun Liu
Journal:  Heart Vessels       Date:  2010-03-26       Impact factor: 2.037

2.  Differences in virus prevalence and load in the hearts of patients with idiopathic dilated cardiomyopathy with and without immune-mediated inflammatory diseases.

Authors:  Robert Dennert; Pieter van Paassen; Petra Wolffs; Catrien Bruggeman; Sebastiaan Velthuis; Susanne Felix; Robert-Jan van Suylen; Harry J Crijns; Jan Willem Cohen Tervaert; Stephane Heymans
Journal:  Clin Vaccine Immunol       Date:  2012-06-13

Review 3.  Clinical significance of inflammation factors in acute coronary syndrome from pathogenic toxin.

Authors:  Yan Feng; Jing-chun Zhang; Rui-xi Xi
Journal:  Chin J Integr Med       Date:  2009-08-18       Impact factor: 1.978

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.